322690-62-0

Usage

General Description

5H-Pyrrolo[2,1-a]isoindol-5-one, 9-amino- is a chemical compound with the molecular formula C11H8N2O. It is a heterocyclic compound that contains a pyrroloisoindole ring system with an amino group substitution at the ninth position. 5H-Pyrrolo[2,1-a]isoindol-5-one, 9-amino- has potential applications in the field of pharmaceuticals and organic synthesis. It can serve as a building block for the synthesis of various organic compounds and may also have biological activity that could be of interest for drug development. Overall, 5H-Pyrrolo[2,1-a]isoindol-5-one, 9-amino- is a versatile compound with potential uses in various areas of chemistry and medicine.

Upstream product

• 391937-33-0 1-(2-bromo-3-nitrobenzoyl)-1H-pyrrole 
• 322692-75-1 9-nitro-5H-pyrrolo[2,1-α]isoindol-5-one 
• 573-54-6 2-bromo-3-nitro-benzoic acid 
• 6286-36-8 2-bromo-3-nitrobenzoic acid chloride 

Relevant academic research and scientific papers

Structure-based generation of a new class of potent Cdk4 inhibitors: New de novo design strategy and library design

As a first step in structure-based design of highly selective and potent Cdk4 inhibitors, we performed structure-based generation of a novel series of Cdk4 inhibitors. A Cdk4 homology model was constructed according to X-ray analysis of an activated form of Cdk2. Using this model, we applied a new de novo design strategy which combined the de novo design program LEGEND with our in-house structure selection supporting system SEEDS to generate new scaffold candidates. In this way, four classes of scaffold candidates including diarylurea were identified. By constructing diarylurea informer libraries based on the structural requirements of Cdk inhibitors in the ATP binding pocket of the Cdk4 model, we were able to identify a potent Cdk4 inhibitor N-(9-oxo-9H-fluoren-4-yl)-N′-pyridin-2-ylurea 15 (IC50 = 0.10 μM), together with preliminary SAR. We performed a docking study between 15 and the Cdk4 model and selected a reasonable binding mode which is consistent with the SAR. Further modification based on the proposed binding mode provided a more potent compound, N-[(9bR)-5-oxo2,3,5,9b-tetrahydro-1H-pyrrolo[2,1-a]isoindol-9-yl]-N′ -pyridin-2-ylurea 26a (IC50 = 0.042 μM), X-ray analysis of which was accomplished by the soaking method. The predicted binding mode of 15 in Cdk4 was validated by X-ray analysis of the Cdk2-26a complex.